Overview

Efficacy and Tolerability of Combination Varenicline With Hydroxyzine as a Potential Smoking Cessation Treatment

Status:
Completed
Trial end date:
2019-12-15
Target enrollment:
Participant gender:
Summary
This open-label study will evaluate hydroxyzine, a first-generation antihistamine, combined with varenicline, to help smokers abstain from smoking during a 12-week trial period by diminishing the nausea, stress, anxiety, and sleep disturbances associated with the use of varenicline and with nicotine withdrawal.
Phase:
Phase 4
Details
Lead Sponsor:
Rose Research Center, LLC
Collaborator:
Foundation for a Smoke-Free World
Treatments:
Hydroxyzine
Varenicline